定制潜在天然化合物用于治疗管腔型乳腺癌。

Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer.

作者信息

da Silva Fernanda Cardoso, Brandão Douglas Cardoso, Ferreira Everton Allan, Siqueira Raoni Pais, Ferreira Helen Soares Valença, Da Silva Filho Ademar Alves, Araújo Thaise Gonçalves

机构信息

Laboratory of Genetics and Biotechnology, Institute of Biotechnology, Universidade Federal de Uberlândia, Patos de Minas 38700-002, MG, Brazil.

Department of Pharmaceutical Sciences, Faculty of Pharmacy, Federal University of Juiz de Fora, Juiz de Fora 36036-900, MG, Brazil.

出版信息

Pharmaceuticals (Basel). 2023 Oct 16;16(10):1466. doi: 10.3390/ph16101466.

DOI:10.3390/ph16101466

PMID:37895937

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10610388/

Abstract

Breast cancer (BC) is the most diagnosed cancer worldwide, mainly affecting the epithelial cells from the mammary glands. When it expresses the estrogen receptor (ER), the tumor is called luminal BC, which is eligible for endocrine therapy with hormone signaling blockade. Hormone therapy is essential for the survival of patients, but therapeutic resistance has been shown to be worrying, significantly compromising the prognosis. In this context, the need to explore new compounds emerges, especially compounds of plant origin, since they are biologically active and particularly promising. Natural products are being continuously screened for treating cancer due to their chemical diversity, reduced toxicity, lower side effects, and low price. This review summarizes natural compounds for the treatment of luminal BC, emphasizing the activities of these compounds in ER-positive cells. Moreover, their potential as an alternative to endocrine resistance is explored, opening new opportunities for the design of optimized therapies.

摘要

乳腺癌（BC）是全球诊断出的最常见癌症，主要影响乳腺上皮细胞。当它表达雌激素受体（ER）时，该肿瘤被称为管腔型乳腺癌，适合通过激素信号阻断进行内分泌治疗。激素疗法对患者的生存至关重要，但治疗耐药性已被证明令人担忧，严重影响预后。在这种情况下，出现了探索新化合物的需求，特别是植物来源的化合物，因为它们具有生物活性且特别有前景。由于天然产物具有化学多样性、低毒性、低副作用和低成本，人们一直在不断筛选用于治疗癌症的天然产物。本综述总结了用于治疗管腔型乳腺癌的天然化合物，强调了这些化合物在ER阳性细胞中的活性。此外，还探讨了它们作为内分泌耐药替代方案的潜力，为优化治疗方案的设计开辟了新机会。